Cardiff Oncology Inc Financials
Cardiff Oncology Inc (CRDF) reported $593K in revenue for fiscal year 2025, down 13.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage spending still dominates a tiny revenue base, while shrinking liquidity and rising leverage shape the financing profile.
Operating cash flow of-$37.9M nearly matches free cash flow of-$38.0M in FY2025, showing that reported cash use is primarily operating spending rather than a major gap created by capital investment. Meanwhile, the current ratio fell from 22.3x in FY2021 to 3.7x in FY2025, showing liquidity compression as the asset base contracted.
Research and development was
Shares outstanding reached 68.3M in FY2025, up from FY2023, indicating dilution accompanied the funding pattern; the reported liquidity measure equaled 21.3 months of annual operating outflow, a historical comparison rather than a forecast.
Financial Health Signals
Cardiff Oncology Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cardiff Oncology Inc scores -8.70, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($76.6M) relative to total liabilities ($16.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cardiff Oncology Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Cardiff Oncology Inc reported a net loss of $46K while operations used $37.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Cardiff Oncology Inc generated $593K in revenue in fiscal year 2025. This represents a decrease of 13.2% from the prior year.
Cardiff Oncology Inc's EBITDA was -$48.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 0.7% from the prior year.
Cardiff Oncology Inc reported -$46K in net income in fiscal year 2025. This represents a decrease of 0.9% from the prior year.
Cardiff Oncology Inc earned -$0.69 per diluted share (EPS) in fiscal year 2025. This represents an increase of 27.4% from the prior year.
Cash & Balance Sheet
Cardiff Oncology Inc recorded an outflow of $38.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 0.5% from the prior year.
Cardiff Oncology Inc held $17.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Cardiff Oncology Inc's net profit margin was -7.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.1 percentage points from the prior year.
Cardiff Oncology Inc's ROE was -0.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cardiff Oncology Inc invested $35.3M in research and development in fiscal year 2025. This represents a decrease of 4.1% from the prior year.
Cardiff Oncology Inc invested $44K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 45.0% from the prior year.
Not reported for fiscal year 2025.
CRDF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $508K | $593K-13.2% | $683K+40.0% | $488K+26.4% | $386K+7.5% | $359K-1.9% | $366K+49.6% | $245K-35.3% | $378K-25.1% | $505K+32.6% | $381K+21.8% | $313K+11.6% | $280K+8.1% | $259K-42.4% | $450K+74.8% | $258K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $597K-67.0% | $1.8M+4.7% | $1.7M+175.0% | $629K+3974.8% | $15K | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $245K+211.6% | -$219K+83.2% | -$1.3M+3.2% | -$1.3M-326.5% | -$316K-219.5% | $265K | N/A | N/A | N/A |
| R&D Expenses | $26.0M | $35.3M-4.1% | $36.9M+12.2% | $32.9M+21.2% | $27.1M+55.7% | $17.4M+54.9% | $11.2M+0.7% | $11.2M+36.7% | $8.2M+3.6% | $7.9M-47.5% | $15.0M+41.7% | $10.6M+59.0% | $6.7M+68.8% | $3.9M+105.6% | $1.9M+110.9% | $911K |
| SG&A Expenses | $16.8M | $14.2M+14.0% | $12.5M-4.3% | $13.0M-1.0% | $13.2M+11.3% | $11.8M+44.1% | $8.2M+42.6% | $5.8M-28.0% | $8.0M-43.8% | $14.2M+24.0% | $11.5M+44.9% | $7.9M+36.3% | $5.8M-17.0% | $7.0M+107.2% | $3.4M+45.4% | $2.3M |
| Operating Income | -$42.3M | -$49.0M-0.6% | -$48.7M-7.1% | -$45.4M-13.8% | -$39.9M-38.3% | -$28.9M-51.2% | -$19.1M-14.4% | -$16.7M+2.2% | -$17.1M+33.4% | -$25.6M+36.2% | -$40.1M-58.8% | -$25.3M-69.1% | -$14.9M-39.8% | -$10.7M-120.5% | -$4.8M-62.9% | -$3.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $2K | $0-100.0% | $25K-97.5% | $1.0M-38.2% | $1.7M+9.8% | $1.5M+80.9% | $843K+4858.9% | $17K | N/A | $57K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Net Income | $5.8M | -$46K-0.9% | -$45K-9.6% | -$41K+99.9% | -$38.7M-36.8% | -$28.3M-46.5% | -$19.3M-17.6% | -$16.4M+0.3% | -$16.5M+33.9% | -$24.9M+36.5% | -$39.2M-42.7% | -$27.5M-91.8% | -$14.3M-21.3% | -$11.8M-2.1% | -$11.6M-416.5% | -$2.2M |
| EPS (Diluted) | — | -$0.69+27.4% | -$0.95-2.2% | -$0.93 | -$0.89-21.9% | -$0.73 | -$1.08 | N/A | -$8.26 | -$51.76 | -$1.37-13.2% | -$1.21-37.5% | -$0.88-25.7% | -$0.70+21.3% | -$0.89 | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRDF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $61.9M-36.3% | $97.2M+19.1% | $81.6M-29.7% | $116.2M-22.3% | $149.5M+11.0% | $134.7M+929.5% | $13.1M-7.7% | $14.2M+15.4% | $12.3M-72.0% | $44.0M-38.5% | $71.4M+147.2% | $28.9M+6.4% | $27.2M+132.8% | $11.7M+1022.4% | $1.0M |
| Current Assets | $60.1M-36.7% | $95.1M+22.8% | $77.4M-30.4% | $111.3M-23.8% | $146.1M+9.6% | $133.4M+1074.6% | $11.4M-11.1% | $12.8M+34.8% | $9.5M-75.7% | $39.0M-43.0% | $68.4M+146.7% | $27.7M+6.3% | $26.1M+136.0% | $11.0M+1211.9% | $842K |
| Cash & Equivalents | $17.5M-66.1% | $51.5M+137.7% | $21.7M+32.5% | $16.3M+36.9% | $11.9M-90.9% | $131.0M+1184.7% | $10.2M-11.0% | $11.5M+39.2% | $8.2M-40.9% | $13.9M-79.4% | $67.5M | N/A | $25.8M+138.8% | $10.8M+1444.9% | $700K |
| Accounts Receivable | $182K-76.5% | $773K+168.4% | $288K-62.6% | $771K+44.1% | $535K+67.2% | $320K+57.3% | $203K+21.3% | $168K+117.6% | $77K-23.3% | $100K+1.7% | $99K+74.2% | $57K-28.2% | $79K-53.1% | $168K+69.8% | $99K |
| Total Liabilities | $16.5M+15.8% | $14.2M+19.7% | $11.9M+20.8% | $9.8M+7.9% | $9.1M+38.9% | $6.6M+13.7% | $5.8M+41.3% | $4.1M-29.3% | $5.8M-76.1% | $24.2M+6.3% | $22.7M+10.7% | $20.5M+203.8% | $6.8M-28.8% | $9.5M+80.2% | $5.3M |
| Current Liabilities | $16.4M+22.1% | $13.4M+28.6% | $10.4M+33.7% | $7.8M+19.0% | $6.6M+7.2% | $6.1M+28.0% | $4.8M+63.6% | $2.9M-25.9% | $3.9M-49.4% | $7.8M-4.9% | $8.2M+82.7% | $4.5M+123.4% | $2.0M+175.0% | $730K-48.9% | $1.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $14.2M+26.1% | $11.2M-13.8% | $13.1M+3941.2% | $323K | N/A | N/A |
| Total Equity | $45.4M-45.3% | $82.9M+18.9% | $69.7M-34.4% | $106.3M-24.3% | $140.4M+9.6% | $128.2M+1652.7% | $7.3M-27.5% | $10.1M+55.0% | $6.5M-67.1% | $19.8M-59.4% | $48.7M+483.3% | $8.3M-59.1% | $20.4M+840.1% | $2.2M+151.3% | -$4.2M |
| Retained Earnings | -$430.0M-11.9% | -$384.2M-13.1% | -$339.5M-13.9% | -$298.1M-14.7% | -$259.8M-12.2% | -$231.5M-10.8% | -$208.9M-8.7% | -$192.2M-11.1% | -$173.0M-16.8% | -$148.1M-36.0% | -$108.9M-33.8% | -$81.4M-21.4% | -$67.0M-21.4% | -$55.2M-26.6% | -$43.6M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
CRDF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.9M | -$37.9M-0.6% | -$37.7M-22.0% | -$30.9M+8.7% | -$33.8M-46.8% | -$23.0M-41.2% | -$16.3M-23.0% | -$13.3M-0.5% | -$13.2M+43.3% | -$23.3M+25.0% | -$31.0M-40.3% | -$22.1M-73.8% | -$12.7M-73.9% | -$7.3M-48.3% | -$4.9M-155.6% | -$1.9M |
| Capital Expenditures | N/A | $44K-45.0% | $80K-86.3% | $582K-42.1% | $1.0M+390.7% | $205K-2.8% | $211K+212.0% | $68K+1225.9% | $5K-95.0% | $101K-87.7% | $823K-63.3% | $2.2M+516.9% | $363K-44.1% | $650K+137.1% | $274K+17837.2% | $2K |
| Free Cash Flow | N/A | -$38.0M-0.5% | -$37.8M-20.0% | -$31.5M+9.6% | -$34.8M-49.8% | -$23.2M-40.7% | -$16.5M-23.9% | -$13.3M-1.0% | -$13.2M+43.5% | -$23.4M+26.6% | -$31.9M-30.8% | -$24.4M-86.1% | -$13.1M-64.3% | -$8.0M-53.0% | -$5.2M-169.6% | -$1.9M |
| Investing Cash Flow | $36.4M | $1.3M-90.2% | $13.7M-62.1% | $36.2M-5.1% | $38.1M+129.0% | -$131.4M-62197.6% | -$211K-212.0% | -$68K-396.0% | $23K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $2.8M | $2.6M-95.2% | $53.8M | $0-100.0% | $75K-99.8% | $35.5M-74.2% | $137.3M+1036.9% | $12.1M-26.4% | $16.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRDF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 100.0%+157.9pp | -57.9% | -258.4% | -354.1% | -101.1% | 94.5% | N/A | N/A | N/A |
| Operating Margin | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -8037.6% | -5214.8% | -6817.8% | -4507.6% | -5064.4% | -10534.9% | -8079.5% | -5334.2% | -4123.7% | -1076.6% | -1155.2% |
| Net Margin | -7.7%-1.1pp | -6.7%+1.8pp | -8.5% | -10026.9% | -7880.5% | -5275.2% | -6709.7% | -4351.1% | -4928.1% | -10287.8% | -8782.0% | -5113.0% | -4555.9% | -2567.9% | -868.9% |
| Return on Equity | -0.1%-0.1pp | -0.1%0.0pp | -0.1%+36.3pp | -36.4%-16.2pp | -20.2%-5.1pp | -15.1%+209.4pp | -224.5%-61.2pp | -163.2%+219.6pp | -382.8%-184.5pp | -198.3%-141.9pp | -56.4%+115.2pp | -171.6%-113.6pp | -57.9%+475.3pp | -533.2% | N/A |
| Return on Assets | -0.1%0.0pp | -0.1%0.0pp | -0.1%+33.3pp | -33.3%-14.4pp | -18.9%-4.6pp | -14.3%+111.1pp | -125.4%-9.3pp | -116.1%+86.6pp | -202.7%-113.5pp | -89.2%-50.8pp | -38.5%+11.1pp | -49.6%-6.1pp | -43.5%+55.7pp | -99.2%+116.3pp | -215.5% |
| Current Ratio | 3.67-3.4x | 7.08-0.3x | 7.41-6.8x | 14.25-8.0x | 22.28+0.5x | 21.79+19.4x | 2.37-2.0x | 4.37+2.0x | 2.40-2.6x | 5.00-3.3x | 8.34+2.2x | 6.18-6.8x | 12.98-2.2x | 15.13+14.5x | 0.59 |
| Debt-to-Equity | 0.36+0.2x | 0.170.0x | 0.17+0.1x | 0.090.0x | 0.070.0x | 0.05-0.7x | 0.79+0.4x | 0.41+0.4x | 0.00-0.7x | 0.72+0.5x | 0.23-1.3x | 1.56+1.5x | 0.02-4.4x | 4.38 | N/A |
| FCF Margin | -6402.5% | -5530.4% | -6448.6% | -9022.3% | -6474.9% | -4515.4% | -5451.1% | -3490.1% | -4626.4% | -8361.5% | -7787.4% | -4672.3% | -3073.2% | -1156.5% | -749.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Cardiff Oncology Inc Ranks
Frequently Asked Questions
What is Cardiff Oncology Inc's annual revenue?
Cardiff Oncology Inc (CRDF) reported $593K in total revenue for fiscal year 2025. This represents a -13.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cardiff Oncology Inc's revenue growing?
Cardiff Oncology Inc (CRDF) revenue declined by 13.2% year-over-year, from $683K to $593K in fiscal year 2025.
Is Cardiff Oncology Inc profitable?
No, Cardiff Oncology Inc (CRDF) reported a net income of -$46K in fiscal year 2025, with a net profit margin of -7.7%.
What is Cardiff Oncology Inc's EBITDA?
Cardiff Oncology Inc (CRDF) had EBITDA of -$48.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cardiff Oncology Inc's net profit margin?
Cardiff Oncology Inc (CRDF) had a net profit margin of -7.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cardiff Oncology Inc's return on equity (ROE)?
Cardiff Oncology Inc (CRDF) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cardiff Oncology Inc's free cash flow?
Cardiff Oncology Inc (CRDF) recorded an outflow of $38.0M in free cash flow during fiscal year 2025. This represents a -0.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cardiff Oncology Inc's operating cash flow?
Cardiff Oncology Inc (CRDF) recorded an outflow of $37.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cardiff Oncology Inc's total assets?
Cardiff Oncology Inc (CRDF) had $61.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cardiff Oncology Inc's capital expenditures?
Cardiff Oncology Inc (CRDF) invested $44K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cardiff Oncology Inc spend on research and development?
Cardiff Oncology Inc (CRDF) invested $35.3M in research and development during fiscal year 2025.
What is Cardiff Oncology Inc's current ratio?
Cardiff Oncology Inc (CRDF) had a current ratio of 3.67 as of fiscal year 2025, which is generally considered healthy.
What is Cardiff Oncology Inc's debt-to-equity ratio?
Cardiff Oncology Inc (CRDF) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cardiff Oncology Inc's return on assets (ROA)?
Cardiff Oncology Inc (CRDF) had a return on assets of -0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Cardiff Oncology Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cardiff Oncology Inc (CRDF) held $67.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $37.9M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cardiff Oncology Inc's Altman Z-Score?
Cardiff Oncology Inc (CRDF) has an Altman Z-Score of -8.70, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cardiff Oncology Inc's Piotroski F-Score?
Cardiff Oncology Inc (CRDF) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cardiff Oncology Inc's earnings high quality?
Cardiff Oncology Inc (CRDF) reported a net loss of $46K while operations used $37.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.